Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vivus Inc (VVUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 120,889
  • Shares Outstanding, K 105,580
  • Annual Sales, $ 124,260 K
  • Annual Income, $ 23,300 K
  • 36-Month Beta 0.85
  • Price/Sales 1.01
  • Price/Cash Flow 2.84
  • Price/Book 6.99

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.11 +3.15%
on 07/27/17
1.32 -13.26%
on 07/11/17
-0.06 (-4.58%)
since 06/27/17
3-Month
0.99 +15.66%
on 05/16/17
1.38 -17.03%
on 06/07/17
+0.12 (+11.17%)
since 04/27/17
52-Week
0.93 +23.12%
on 08/02/16
1.47 -22.11%
on 12/07/16
+0.06 (+6.02%)
since 07/27/16

Most Recent Stories

More News
VIVUS Settles with Teva on Weight Management Drug Generic

VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight...

AGEN : 4.48 (-14.83%)
VVUS : 1.14 (-3.78%)
RDY : 38.30 (-8.09%)
TEVA : 32.45 (-1.79%)
VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation

CAMPBELL, CA--(Marketwired - Jul 5, 2017) - VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Actavis Laboratories FL (Actavis) resolving patent litigation...

VVUS : 1.14 (-3.78%)
VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation

CAMPBELL, CA--(Marketwired - Jul 5, 2017) - VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Actavis Laboratories FL (Actavis) resolving patent litigation...

VVUS : 1.14 (-3.78%)
BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase

BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).

VVUS : 1.14 (-3.78%)
BMRN : 87.32 (-2.11%)
MEIP : 3.02 (-0.98%)
REGN : 508.41 (-1.40%)
Why is Corcept's Stock Up More Than 60% So Far This Year?

Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period....

CORT : 12.12 (-0.66%)
CELG : 134.15 (-2.61%)
VVUS : 1.14 (-3.78%)
PFE : 33.00 (+0.33%)
Roche (RHHBY) Launches Cobas Test for Bacterial Infections

Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at...

BAYRY : 125.9200 (-3.56%)
VVUS : 1.14 (-3.78%)
RHHBY : 31.6100 (-0.16%)
REGN : 508.41 (-1.40%)
Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label

Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion of its colorectal cancer drug, Vectibix.

VVUS : 1.14 (-3.78%)
REGN : 508.41 (-1.40%)
AMGN : 172.15 (-2.13%)
GSK : 40.75 (-0.24%)
Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU

Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.

VVUS : 1.14 (-3.78%)
ABBV : 71.73 (-1.18%)
SGEN : 52.97 (-3.73%)
RHHBY : 31.6100 (-0.16%)
Acorda Files NDA for Parkinson's Disease Candidate Inbrija

Acorda Therapeutics, Inc. (ACOR) has submitted a new drug application to FDA for its late stage pipeline candidate Inbrija for treatment of patients suffering from Parkinson's disease.

BAYRY : 125.9200 (-3.56%)
VVUS : 1.14 (-3.78%)
ACOR : 21.70 (-3.77%)
REGN : 508.41 (-1.40%)
Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA

Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu.

VVUS : 1.14 (-3.78%)
MEIP : 3.02 (-0.98%)
VRX : 17.13 (-3.60%)
SNY : 48.09 (+0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity...

See More

Support & Resistance

2nd Resistance Point 1.23
1st Resistance Point 1.19
Last Price 1.14
1st Support Level 1.11
2nd Support Level 1.07

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.